Skip to content

Quiet period ends on Acutus Medical; stock rallies on analysts ratings

August 31, 2020

Analyst coverage opens up on Acutus Medical (AFIB +14.1%).

William Blair launches the online marketplace stock with a Outperform rating. Analyst Margaret Kaczor estimates sales of $11.8M in 2020, $55M in 2021, and $125.4M in 2022; he believes better outcomes—particularly for hard-to-treat cases—a better patient/care team experience, and a lower cost to treat should lead to a 120% sales CAGR through 2022.

“Acutus is poised to take share and expand the $5.7B global cardiac ablation market,” Kaczor added.

JPMorgan Chase sets an Overweight rating and price target of $39. Buy ratings have been initiated by Bank of America (PT, 38), BTIG Research (PT, 40) and BofA Securities (PT, 38). Cautious ratings are in from Canaccord Genuity (Hold).

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: